Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stimulating the IGF-1R at the level of the CN has the potential to mitigate erectile dysfunction in men after radical prostatectomy, but further research is needed to evaluate the safety of this growth factor in the setting of prostate cancer.Haney NM, Talwar S, Akula PK, et al.
|
30846112 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-1 elevation led to the accumulation of FOXO3A in the cytosol of prostate tumor cells and downregulation of its target gene Bim, which resulted in the apoptosis inhibition and prostate cancer overgrowth.
|
31312023 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support the hypothesised roles of IGF-I and testosterone in prostate cancer development and/or progression.
|
31755099 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess sex hormones, IGF1, glucose, and advanced glycation end products (AGEs) as potential mediators of the association between diabetes mellitus and prostate cancer.
|
31504635 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechano-growth factor (MGF) is an isoform of IGF1 and its expression has been demonstrated in malignancies including prostate cancer.
|
30952709 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The onset of accelerated prostatic growth, observed on PND 21, associated with an unbalanced estrogen/testosterone ratio and increased circulating IGF-1 in older offspring appears to contribute to the development of prostate carcinoma in groups on gestational low protein and gestational and lactational low protein diets (33 and 50%, respectively).
|
29762647 |
2019 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A comprehensive analysis of polymorphic variants in steroid hormone and insulin-like growth factor-1 metabolism and risk of in situ breast cancer: Results from the Breast and Prostate Cancer Cohort Consortium.
|
29114882 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background The inhibition of insulin-like growth factor receptor-1 (IGF-1R) induces cell cycle arrest and enhancing the effect of castration by delay of progression of human prostate cancer models.
|
29476383 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Men with high serum IGF-1 were more likely to have prostate cancer (highest vs lowest quartile, odds ratio [OR] = 3.35; P<sub>trend</sub> < 0.001).
|
29992746 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circulating insulin-like growth factor-1 (IGF-1) is consistently associated with prostate cancer risk.
|
30165429 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous production of IGF and IGFBPs was verified in CaP cells and clinical CaP specimens.
|
30014700 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased protein intake and body mass index, and increased physical activity and fruit and vegetable intake, following a prostate cancer diagnosis were associated with reduced post-diagnosis serum IGF-I and IGFBP-3.
|
28646365 |
2017 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the carboxyl-terminal of the IGF-1Ec variant (hEc; 24aa) has been associated with osteosarcoma and prostate cancer.
|
28551627 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor cell IGF-1R immunoreactivity was evaluated in clinical PCa bone metastases (n = 61), and positive staining was observed in most cases (74%).
|
28447314 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One hypothesis is that the indirect insulin lowering effect may have an anti-neoplastic action as elevated insulin and insulin like growth factor - 1 (IGF-1) levels play a role in PCa development and progression.
|
28732480 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-I is a potential mechanism underlying the observed associations between milk intake and prostate cancer risk.
|
28361446 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative evaluation of IGF-1/IGF-1R expression combined with molecular assessment of T2E status or ERG protein expression represents a useful marker for tumor progression in localized PCa.
|
28545426 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed associations between IGF-1R and clinical outcomes by immunohistochemistry in diagnostic biopsies of 136 men treated with 55-70 Gy external beam radiotherapy for prostate cancer, comparing results with publicly available transcriptional data in surgically treated patients.
|
28972962 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In1-ghrelin, insulin/IGF-I) in cultured normal prostate cells and PCa-cell lines.
|
27693462 |
2016 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IGF1 and IGFBP3 serum levels did not significantly differ between the PCa and BPH groups.
|
26954072 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer in Pten(-/-)Ptpn1(-/-) mice was characterized by increased cell proliferation and Akt activation, interpreted to reflect a heightened sensitivity to IGF-1 stimulation upon HFD feeding.
|
27020859 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ∼700 men without prostate cancer and two replication cohorts (N ∼ 900 and ∼9,000), we examined the properties of these SNPS as instrumental variables (IVs) for IGF-I, IGF-II, IGFBP-2 and IGFBP-3.
|
27225428 |
2016 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer.
|
25569803 |
2015 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
|
25906745 |
2015 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes.
|
25724697 |
2015 |